Endogenous modulators of inflammatory cell recruitment

Trends in Immunology

Volumn 34, Issue 1, 2013, Pages 1-6

  Hajishengallis, George ^a   Chavakis, Triantafyllos ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD31 ANTIGEN; CD99 ANTIGEN; GALECTIN 1; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; INTEGRIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; JUNCTIONAL ADHESION MOLECULE; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PENTRAXIN 3;

CELL SURFACE; GLYCOSYLATION; HOMEOSTASIS; HUMAN; INFLAMMATION; LEUKOCYTE ADHERENCE; LEUKOCYTE FUNCTION AND CHARACTERISTICS; LEUKOCYTE RECRUITMENT; LOCOMOTION; LYMPHOCYTE; MACROPHAGE; MONOCYTE; NEUTROPHIL; PROTEIN EXPRESSION; REVIEW; THROMBOCYTE AGGREGATION;

CELL MOVEMENT; GALECTINS; HUMANS; INFLAMMATION; LEUKOCYTES; MODELS, IMMUNOLOGICAL;

EID: 84871712393     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.08.003     Document Type: Review

References (66)

1. Chavakis E., et al. Novel aspects in the regulation of the leukocyte adhesion cascade. Thromb. Haemost. 2009, 102:191-197.
2. Luster A.D., et al. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 2005, 6:1182-1190.
3. Langer H.F., Chavakis T. Leukocyte-endothelial interactions in inflammation. J. Cell. Mol. Med. 2009, 13:1211-1220.
4. Ley K., et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 2007, 7:678-689.
5. Vestweber D. Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium. Immunol. Rev. 2007, 218:178-196.
6. Nourshargh S., et al. Breaching multiple barriers: leukocyte motility through venular walls and the interstitium. Nat. Rev. Mol. Cell Biol. 2010, 11:366-378.
7. Auffray C., et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007, 317:666-670.
8. Shamri R., et al. Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endothelium-bound chemokines. Nat. Immunol. 2005, 6:497-506.
9. McEver R.P., Zhu C. Rolling cell adhesion. Annu. Rev. Cell Dev. Biol. 2010, 26:363-396.
10. Chavakis T. Leucocyte recruitment in inflammation and novel endogenous negative regulators thereof. Eur. J. Clin. Invest. 2012, 42:686-691.
11. Schenkel A.R., et al. Locomotion of monocytes on endothelium is a critical step during extravasation. Nat. Immunol. 2004, 5:393-400.
12. Phillipson M., et al. Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J. Exp. Med. 2006, 203:2569-2575.
13. Abram C.L., Lowell C.A. The ins and outs of leukocyte integrin signaling. Annu. Rev. Immunol. 2009, 27:339-362.
14. Carman C.V., Springer T.A. Integrin avidity regulation: are changes in affinity and conformation underemphasized?. Curr. Opin. Cell Biol. 2003, 15:547-556.
15. Woodfin A., et al. The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo. Nat. Immunol. 2011, 12:761-769.
16. Deban L., et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat. Immunol. 2010, 11:328-334.
17. Garlanda C., et al. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol. 2005, 23:337-366.
18. Maina V., et al. Coregulation in human leukocytes of the long pentraxin PTX3 and TSG-6. J. Leukoc. Biol. 2009, 86:123-132.
19. Cotena A., et al. Complement dependent amplification of the innate response to a cognate microbial ligand by the long pentraxin PTX3. J. Immunol. 2007, 179:6311-6317.
20. Bottazzi B., et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol. Rev. 2009, 227:9-18.
21. Salio M., et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008, 117:1055-1064.
22. McEver R.P. Selectins: lectins that initiate cell adhesion under flow. Curr. Opin. Cell Biol. 2002, 14:581-586.
23. Gawaz M., et al. Platelets in inflammation and atherogenesis. J. Clin. Invest. 2005, 115:3378-3384.
24. Chavakis T., et al. High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib. J. Biol. Chem. 2003, 278:45375-45381.
25. Santoso S., et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J. Exp. Med. 2002, 196:679-691.
26. Langer H.F., et al. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ. Res. 2012, 110:1202-1210.
27. Zarbock A., et al. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J. Clin. Invest. 2006, 116:3211-3219.
28. Vasta G.R. Galectins as pattern recognition receptors: structure, function, and evolution. Adv. Exp. Med. Biol. 2012, 946:21-36.
29. Cooper D., et al. Novel insights into the inhibitory effects of Galectin-1 on neutrophil recruitment under flow. J. Leukoc. Biol. 2008, 83:1459-1466.
30. Gil C.D., et al. Effect of exogenous galectin-1 on leukocyte migration: modulation of cytokine levels and adhesion molecules. Int. J. Clin. Exp. Pathol. 2010, 4:74-84.
31. Offner H., et al. Recombinant human beta-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1990, 28:177-184.
32. Toscano M.A., et al. Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J. Immunol. 2006, 176:6323-6332.
33. Nieminen J., et al. Galectin-3 interacts with naive and primed neutrophils, inducing innate immune responses. J. Leukoc. Biol. 2005, 78:1127-1135.
34. Kuwabara I., Liu F.T. Galectin-3 promotes adhesion of human neutrophils to laminin. J. Immunol. 1996, 156:3939-3944.
35. Rao S.P., et al. Galectin-3 functions as an adhesion molecule to support eosinophil rolling and adhesion under conditions of flow. J. Immunol. 2007, 179:7800-7807.
36. Li Y., et al. Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation. J. Immunol. 2008, 181:2781-2789.
37. Penta K., et al. Del1 induces integrin signaling and angiogenesis by ligation of alphaVbeta3. J. Biol. Chem. 1999, 274:11101-11109.
38. Hidai C., et al. Discoidin domain of Del1 protein contributes to its deposition in the extracellular matrix. Cell Tissue Res. 2007, 330:83-95.
39. Choi E.Y., et al. Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science 2008, 322:1101-1104.
40. Eskan M.A., et al. The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat. Immunol. 2012, 13:465-473.
41. Pihlstrom B.L., et al. Periodontal diseases. Lancet 2005, 366:1809-1820.
42. Genco R.J., Van Dyke T.E. Prevention: reducing the risk of CVD in patients with periodontitis. Nat. Rev. Cardiol. 2010, 7:479-480.
43. Lalla E., Papapanou P.N. Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nat. Rev. Endocrinol. 2011, 7:738-748.
44. Tonetti M.S., et al. Treatment of periodontitis and endothelial function. N. Engl. J. Med. 2007, 356:911-920.
45. Jeffcoat M., et al. Periodontal infection and preterm birth: successful periodontal therapy reduces the risk of preterm birth. BJOG 2011, 118:250-256.
46. Lundberg K., et al. Periodontitis in RA-the citrullinated enolase connection. Nat. Rev. Rheumatol. 2010, 6:727-730.
47. Kolls J.K., Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476.
48. Stark M.A., et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 2005, 22:285-294.
49. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 2009, 9:556-567.
50. Kempf T., et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ. Res. 2006, 98:351-360.
51. Kempf T., et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat. Med. 2011, 17:581-588.
52. Frangogiannis N.G. Regulation of the inflammatory response in cardiac repair. Circ. Res. 2012, 110:159-173.
53. Carlos T.M. Leukocyte recruitment at sites of tumor: dissonant orchestration. J. Leukoc. Biol. 2001, 70:171-184.
54. Serhan C.N., et al. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008, 8:349-361.
55. Serhan C.N., Petasis N.A. Resolvins and protectins in inflammation resolution. Chem. Rev. 2011, 111:5922-5943.
56. Papayianni A., et al. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J. Immunol. 1996, 156:2264-2272.
57. Fiore S., Serhan C.N. Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction. Biochemistry 1995, 34:16678-16686.
58. Spite M., Serhan C.N. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ. Res. 2010, 107:1170-1184.
59. Spite M., et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009, 461:1287-1291.
60. Chiang N., et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 2012, 484:524-528.
61. Godson C., et al. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 2000, 164:1663-1667.
62. Schwab J.M., et al. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007, 447:869-874.
63. Matzinger P., Kamala T. Tissue-based class control: the other side of tolerance. Nat. Rev. Immunol. 2011, 11:221-230.
64. Stout R.D., Suttles J. Immunosenescence and macrophage functional plasticity: dysregulation of macrophage function by age-associated microenvironmental changes. Immunol. Rev. 2005, 205:60-71.
65. Niederkorn J.Y., Stein-Streilein J. History and physiology of immune privilege. Ocul. Immunol. Inflamm. 2010, 18:19-23.
66. Streilein J.W. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 2003, 3:879-889.